Ernexa Therapeutics Inc
ERNA
Ernexa Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Cash burn of 9.4M TTM vs 3.0M cash on hand = ~4 months runway without financing. Existential liquidity risk.[Free Cash Flow TTM]
- Goodwill of 2.0M is 57% of equity (3.6M) - impairment would devastate already thin capital base.[Goodwill]
- Revenue collapsed 99.8% YoY (1K TTM) while burning 4.6M on R&D - no commercial traction.[Gross Profit 1Y Growth TTM]
Watch Triggers
- Cash and Equivalents: Falls below 1.5M or financing announced — Sub-1.5M triggers going concern; financing terms reveal dilution severity
- Research and Development TTM: Drops >50% from 4.6M — R&D cuts signal pipeline abandonment or pivot to shell company
- Total Revenue TTM: Any material revenue (>100K) — Would indicate commercial progress or licensing deal
Bull Case
Low debt (0.15 D/E) and minimal capex (22K) means any pipeline success flows directly to equity value without debt overhang.
Micro-cap (10.6M) with R&D spend of 4.6M - binary event risk/reward if pipeline advances.
Bear Case
Imminent dilution: 4-month runway forces equity raise at distressed valuation, destroying existing shareholders.
No commercial viability: 1K revenue, -99.8% growth, negative operating margin of -9922x revenue.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ERNA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Dilutive financing or reverse merger likely within 6 months given cash runway constraints
- 4-month cash runway at current burn
- No revenue to fund operations
- R&D spend requires continued capital
Public Strategies Rankings
See how Ernexa Therapeutics Inc ranks across different investment strategies.
Leverage ERNA's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
ERNA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$10.78M | — | ||
$8.28M | — | ||
0.02 | — | ||
$1,000 | -99.8% | — | |
$57.29 | — | ||
-992,200% | -988802.5% | — | |
-1,834,100% | -1826586.1% | — | |
$-9.44M | — | ||
0.00 | — | ||
Beta 5Y (Monthly) | unknown | — |
ERNA Dividend History
ERNA Stock Splits
ERNA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/07/25 | 09/30/25 | 10-Q | |
08/13/25 | 06/30/25 | 10-Q | |
05/07/25 | 03/31/25 | 10-Q | |
03/12/25 | 12/31/24 | Unknown | |
11/12/24 | 09/30/24 | 10-Q | |
08/13/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
03/14/24 | 12/31/23 | 10-K | |
11/13/23 | 09/30/23 | 10-Q | |
08/11/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/20/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/11/22 | 06/30/22 | 10-Q | |
07/01/22 | 03/31/22 | 10-Q | |
04/15/22 | 12/31/21 | 10-K | |
11/12/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
05/17/21 | 03/31/21 | 10-Q | |
07/01/22 | 12/31/20 | 10-K/A | |
11/12/21 | 09/30/20 | 10-Q | |
08/13/21 | 06/30/20 | 10-Q | |
05/17/21 | 03/31/20 | 10-Q |